Amicus Therapeutics (NASDAQ:FOLD – Get Rating) was downgraded by equities researchers at StockNews.com from a “buy” rating to a “hold” rating in a report issued on Sunday.
Other equities research analysts have also recently issued reports about the stock. The Goldman Sachs Group upped their price target on shares of Amicus Therapeutics from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Thursday, March 2nd. BTIG Research boosted their price target on shares of Amicus Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Wednesday, January 18th. Finally, UBS Group upped their price objective on Amicus Therapeutics from $15.00 to $17.00 and gave the company a “buy” rating in a research note on Thursday, March 2nd. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $14.75.
Amicus Therapeutics Stock Down 3.2 %
Shares of Amicus Therapeutics stock opened at $11.24 on Friday. The company has a debt-to-equity ratio of 3.19, a current ratio of 3.05 and a quick ratio of 2.88. The firm has a market cap of $3.18 billion, a price-to-earnings ratio of -13.71 and a beta of 0.82. The stock has a 50-day simple moving average of $12.62 and a 200-day simple moving average of $11.69. Amicus Therapeutics has a 52-week low of $5.91 and a 52-week high of $13.84.
Insider Transactions at Amicus Therapeutics
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the stock. Norges Bank bought a new position in Amicus Therapeutics during the 4th quarter worth approximately $65,935,000. Pictet Asset Management SA grew its holdings in shares of Amicus Therapeutics by 442.0% in the 3rd quarter. Pictet Asset Management SA now owns 3,485,302 shares of the biopharmaceutical company’s stock valued at $36,387,000 after buying an additional 2,842,220 shares during the period. State Street Corp increased its position in shares of Amicus Therapeutics by 16.6% in the 2nd quarter. State Street Corp now owns 13,918,315 shares of the biopharmaceutical company’s stock valued at $149,483,000 after buying an additional 1,983,752 shares in the last quarter. Fiera Capital Corp raised its stake in Amicus Therapeutics by 29.2% during the 4th quarter. Fiera Capital Corp now owns 5,189,157 shares of the biopharmaceutical company’s stock worth $63,360,000 after buying an additional 1,172,602 shares during the period. Finally, Healthcare of Ontario Pension Plan Trust Fund raised its stake in Amicus Therapeutics by 50.8% during the 3rd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 2,626,600 shares of the biopharmaceutical company’s stock worth $27,422,000 after buying an additional 884,400 shares during the period.
Amicus Therapeutics Company Profile
Amicus Therapeutics, Inc operates as a biotechnology company. The firm focuses on discovering, developing and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio.
- Get a free copy of the StockNews.com research report on Amicus Therapeutics (FOLD)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.